Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Autoimmune Disorders

  Free Subscription


Articles published in J Neurol

Retrieve available abstracts of 198 articles:
HTML format
Text format



Single Articles


    October 2019
  1. SINNECKER T, Ruberte E, Schadelin S, Canova V, et al
    New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
    J Neurol. 2019 Oct 14. pii: 10.1007/s00415-019-09565.
    PubMed     Text format     Abstract available


  2. KAMM CP, Barin L, Gobbi C, Pot C, et al
    Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
    J Neurol. 2019 Oct 8. pii: 10.1007/s00415-019-09563.
    PubMed     Text format     Abstract available


  3. ROMEO MAL, Garassino MC, Moiola L, Galli G, et al
    Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.
    J Neurol. 2019 Oct 4. pii: 10.1007/s00415-019-09562.
    PubMed     Text format    


  4. MORALES FS, Koralnik IJ, Gautam S, Samaan S, et al
    Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate.
    J Neurol. 2019 Oct 3. pii: 10.1007/s00415-019-09557.
    PubMed     Text format     Abstract available


    September 2019
  5. MARGONI M, Rinaldi F, Riccardi A, Franciotta S, et al
    No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab.
    J Neurol. 2019 Sep 27. pii: 10.1007/s00415-019-09554.
    PubMed     Text format     Abstract available


  6. PAOLICELLI D, Lucisano G, Manni A, Avolio C, et al
    Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register.
    J Neurol. 2019 Sep 18. pii: 10.1007/s00415-019-09531.
    PubMed     Text format     Abstract available


  7. GUGER M, Enzinger C, Leutmezer F, Kraus J, et al
    Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2019 Sep 17. pii: 10.1007/s00415-019-09535.
    PubMed     Text format     Abstract available


  8. GRANELLA F, Tsantes E, Graziuso S, Bazzurri V, et al
    Spinal cord lesions are frequently asymptomatic in relapsing-remitting multiple sclerosis: a retrospective MRI survey.
    J Neurol. 2019 Sep 7. pii: 10.1007/s00415-019-09526.
    PubMed     Text format     Abstract available


  9. SHEMA-SHIRATZKY S, Gazit E, Sun R, Regev K, et al
    Deterioration of specific aspects of gait during the instrumented 6-min walk test among people with multiple sclerosis.
    J Neurol. 2019 Sep 6. pii: 10.1007/s00415-019-09500.
    PubMed     Text format     Abstract available


  10. CHAMBERLAIN JL, Huda S, Whittam DH, Matiello M, et al
    Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.
    J Neurol. 2019 Sep 3. pii: 10.1007/s00415-019-09498.
    PubMed     Text format     Abstract available


    August 2019
  11. STORELLI L, Rocca MA, Pantano P, Pagani E, et al
    MRI quality control for the Italian Neuroimaging Network Initiative: moving towards big data in multiple sclerosis.
    J Neurol. 2019 Aug 17. pii: 10.1007/s00415-019-09509.
    PubMed     Text format     Abstract available


    July 2019
  12. INOJOSA H, Proschmann U, Akgun K, Ziemssen T, et al
    A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition.
    J Neurol. 2019 Jul 30. pii: 10.1007/s00415-019-09489.
    PubMed     Text format     Abstract available


  13. RASTAS C, Sirignano D, Barner A, Bruno-Murtha LA, et al
    Legionella infection associated with dimethyl fumarate used for treatment of multiple sclerosis.
    J Neurol. 2019 Jul 26. pii: 10.1007/s00415-019-09483.
    PubMed     Text format    


  14. KIMURA K, Okada Y, Fujii C, Komatsu K, et al
    Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.
    J Neurol. 2019 Jul 24. pii: 10.1007/s00415-019-09461.
    PubMed     Text format     Abstract available


  15. MO XB, Lei SF, Qian QY, Guo YF, et al
    Integrative analysis revealed potential causal genetic and epigenetic factors for multiple sclerosis.
    J Neurol. 2019 Jul 18. pii: 10.1007/s00415-019-09476.
    PubMed     Text format     Abstract available


  16. MICHAEL G, Christian E, Fritz L, Jorg K, et al
    Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    J Neurol. 2019 Jul 16. pii: 10.1007/s00415-019-09464.
    PubMed     Text format     Abstract available


  17. RAIMO S, Trojano L, Gaita M, Spitaleri D, et al
    High openness and high extroversion are linked with better time-based prospective memory in multiple sclerosis.
    J Neurol. 2019 Jul 16. pii: 10.1007/s00415-019-09460.
    PubMed     Text format     Abstract available


    June 2019
  18. BERENGUER-RUIZ L, Gimenez-Martinez J, Palazon-Bru A, Sempere AP, et al
    Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
    J Neurol. 2019 Jun 29. pii: 10.1007/s00415-019-09450.
    PubMed     Text format     Abstract available


  19. FRAU J, Sacca F, Signori A, Baroncini D, et al
    Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
    J Neurol. 2019 Jun 17. pii: 10.1007/s00415-019-09424.
    PubMed     Text format     Abstract available


  20. SPARACO M, Lavorgna L, Bonavita S
    Psychiatric disorders in multiple sclerosis.
    J Neurol. 2019 Jun 13. pii: 10.1007/s00415-019-09426.
    PubMed     Text format     Abstract available


  21. CUNNIFFE N, Coles A
    Promoting remyelination in multiple sclerosis.
    J Neurol. 2019 Jun 12. pii: 10.1007/s00415-019-09421.
    PubMed     Text format     Abstract available


  22. KEARNS PKA, Paton M, O'Neill M, Waters C, et al
    Regional variation in the incidence rate and sex ratio of multiple sclerosis in Scotland 2010-2017: findings from the Scottish Multiple Sclerosis Register.
    J Neurol. 2019 Jun 11. pii: 10.1007/s00415-019-09413.
    PubMed     Text format     Abstract available


    May 2019
  23. SODERHOLM J, Yilmaz A, Svenningsson A, Busch K, et al
    Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.
    J Neurol. 2019 May 31. pii: 10.1007/s00415-019-09397.
    PubMed     Text format     Abstract available


  24. LI H, Hu F, Zhang Y, Li K, et al
    Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09395.
    PubMed     Text format     Abstract available


  25. GAETANI L, Salvadori N, Lisetti V, Eusebi P, et al
    Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis.
    J Neurol. 2019 May 25. pii: 10.1007/s00415-019-09398.
    PubMed     Text format     Abstract available


  26. DUDEK MIR, Thies K, Kammenhuber S, Bosel J, et al
    HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab.
    J Neurol. 2019 May 21. pii: 10.1007/s00415-019-09391.
    PubMed     Text format    


  27. ALEKSEEVA TM, Kreis OA, Gavrilov YV, Valko PO, et al
    Impact of autoimmune comorbidity on fatigue, sleepiness and mood in myasthenia gravis.
    J Neurol. 2019 May 21. pii: 10.1007/s00415-019-09374.
    PubMed     Text format     Abstract available


  28. LANGENBRUCH L, Kramer J, Guler S, Moddel G, et al
    Seizures and epilepsy in multiple sclerosis: epidemiology and prognosis in a large tertiary referral center.
    J Neurol. 2019 May 8. pii: 10.1007/s00415-019-09332.
    PubMed     Text format     Abstract available


  29. PANTAVOU KG, Bagos PG
    Season of birth and multiple sclerosis: a systematic review and multivariate meta-analysis.
    J Neurol. 2019 May 4. pii: 10.1007/s00415-019-09346.
    PubMed     Text format     Abstract available


  30. ZIFF OJ, Hoskote C, Keddie S, D'Sa S, et al
    Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome.
    J Neurol. 2019;266:1067-1072.
    PubMed     Text format     Abstract available


  31. WYNFORD-THOMAS R, Jacob A, Tomassini V
    Neurological update: MOG antibody disease.
    J Neurol. 2019;266:1280-1286.
    PubMed     Text format     Abstract available


    April 2019
  32. PUST GEA, Pottgen J, Randerath J, Lau S, et al
    In search of distinct MS-related fatigue subtypes: results from a multi-cohort analysis in 1.403 MS patients.
    J Neurol. 2019 Apr 19. pii: 10.1007/s00415-019-09311.
    PubMed     Text format     Abstract available


  33. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Retraction Note to: Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2019 Apr 11. pii: 10.1007/s00415-019-09292.
    PubMed     Text format     Abstract available


  34. SPINA E, Topa A, Iodice R, Tozza S, et al
    Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP.
    J Neurol. 2019;266:860-865.
    PubMed     Text format     Abstract available


    March 2019
  35. SINGH N, Goyal V
    Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study.
    J Neurol. 2019 Mar 27. pii: 10.1007/s00415-019-09296.
    PubMed     Text format     Abstract available


  36. GAO J, Jones J, Damato EM, Coles A, et al
    Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    J Neurol. 2019 Mar 20. pii: 10.1007/s00415-019-09288.
    PubMed     Text format    


  37. AL-ANSARI A, Robertson NP
    Autoimmune encephalitis: frequency and prognosis.
    J Neurol. 2019 Mar 15. pii: 10.1007/s00415-019-09273.
    PubMed     Text format    


  38. FRAU J, Coghe G, Lorefice L, Fenu G, et al
    Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    J Neurol. 2019 Mar 12. pii: 10.1007/s00415-019-09272.
    PubMed     Text format     Abstract available


  39. NYE CJS, Wagner A, Kousin-Ezewu O, Jones JL, et al
    A case of anaphylaxis to alemtuzumab.
    J Neurol. 2019;266:780-781.
    PubMed     Text format    


  40. SHAYGANNEJAD V, Fayyazi E, Badihian S, Mirmosayyeb O, et al
    Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study.
    J Neurol. 2019;266:642-650.
    PubMed     Text format     Abstract available


    February 2019
  41. TURNER B, Cree BAC, Kappos L, Montalban X, et al
    Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
    J Neurol. 2019 Feb 28. pii: 10.1007/s00415-019-09248.
    PubMed     Text format     Abstract available


  42. RICHTER S, Wagner B, Celius EG
    Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease.
    J Neurol. 2019 Feb 25. pii: 10.1007/s00415-019-09257.
    PubMed     Text format    


  43. PERSSON R, Lee S, Yood MU, Wagner M, et al
    Multi-database study of multiple sclerosis: identification, validation and description of MS patients in two countries.
    J Neurol. 2019 Feb 18. pii: 10.1007/s00415-019-09238.
    PubMed     Text format     Abstract available


  44. JAKIMOVSKI D, Weinstock-Guttman B, Gandhi S, Guan Y, et al
    Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.
    J Neurol. 2019 Feb 13. pii: 10.1007/s00415-019-09208.
    PubMed     Text format     Abstract available


  45. MASSA R, Greco G, Testi M, Rastelli E, et al
    Thymomatous myasthenia gravis: novel association with HLA DQB1*05:01 and strengthened evidence of high clinical and serological severity.
    J Neurol. 2019 Feb 11. pii: 10.1007/s00415-019-09225.
    PubMed     Text format     Abstract available


  46. BLATTNER MS, de Bruin GS, Bucelli RC, Day GS, et al
    Sleep disturbances are common in patients with autoimmune encephalitis.
    J Neurol. 2019 Feb 11. pii: 10.1007/s00415-019-09230.
    PubMed     Text format     Abstract available


  47. LEBRUN-FRENAY C, Moulignier A, Pierrot-Deseilligny C, Benrabah R, et al
    Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.
    J Neurol. 2019 Feb 7. pii: 10.1007/s00415-019-09211.
    PubMed     Text format     Abstract available


  48. KIM SW, Choi YC, Kim SM, Shim HS, et al
    Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis.
    J Neurol. 2019 Feb 6. pii: 10.1007/s00415-019-09222.
    PubMed     Text format     Abstract available


  49. GAMRAOUI S, Mathey G, Debouverie M, Malaplate C, et al
    High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.
    J Neurol. 2019 Feb 1. pii: 10.1007/s00415-019-09212.
    PubMed     Text format     Abstract available


  50. LAURIDO-SOTO O, Brier MR, Simon LE, McCullough A, et al
    Patient characteristics and outcome associations in AMPA receptor encephalitis.
    J Neurol. 2019;266:450-460.
    PubMed     Text format     Abstract available


  51. RAJABALLY YA, Afzal S
    Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2019;266:461-467.
    PubMed     Text format     Abstract available


  52. FISSE AL, Pitarokoili K, Motte J, Gamber D, et al
    Nerve echogenicity and intranerve CSA variability in high-resolution nerve ultrasound (HRUS) in chronic inflammatory demyelinating polyneuropathy (CIDP).
    J Neurol. 2019;266:468-475.
    PubMed     Text format     Abstract available


  53. D'AMICO E, Zanghi A, Sciandra M, Borriello G, et al
    Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience.
    J Neurol. 2019;266:411-416.
    PubMed     Text format     Abstract available


  54. CHALMER TA, Kalincik T, Laursen B, Sorensen PS, et al
    Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy.
    J Neurol. 2019;266:306-315.
    PubMed     Text format     Abstract available


    January 2019
  55. ALCALA C, Gascon F, Perez-Miralles F, Dominguez JA, et al
    Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
    J Neurol. 2019 Jan 19. pii: 10.1007/s00415-019-09195.
    PubMed     Text format     Abstract available


  56. LAVORGNA L, Esposito S, Lanzillo R, Sparaco M, et al
    Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey.
    J Neurol. 2019 Jan 16. pii: 10.1007/s00415-019-09193.
    PubMed     Text format     Abstract available


  57. TOPAKIAN R, Zimprich F, Iglseder S, Embacher N, et al
    High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
    J Neurol. 2019 Jan 16. pii: 10.1007/s00415-019-09191.
    PubMed     Text format     Abstract available


  58. HARTUNG HP, Graf J, Kremer D
    Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study.
    J Neurol. 2019 Jan 4. pii: 10.1007/s00415-018-09169.
    PubMed     Text format     Abstract available


  59. PFEUFFER S, Schmidt R, Straeten FA, Pul R, et al
    Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
    J Neurol. 2019;266:165-173.
    PubMed     Text format     Abstract available


    December 2018
  60. SONG J, Westerlind H, McKay KA, Almqvist C, et al
    Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study.
    J Neurol. 2018 Dec 21. pii: 10.1007/s00415-018-9163.
    PubMed     Text format     Abstract available


  61. AL-HAKEM H, Sindrup SH, Andersen H, de la Cour CD, et al
    Guillain-Barre syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity.
    J Neurol. 2018 Dec 7. pii: 10.1007/s00415-018-9151.
    PubMed     Text format     Abstract available


  62. JOHNEN A, Burkner PC, Landmeyer NC, Ambrosius B, et al
    Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS).
    J Neurol. 2018 Dec 4. pii: 10.1007/s00415-018-9142.
    PubMed     Text format     Abstract available


  63. BRAUNE S, Grimm S, van Hovell P, Freudensprung U, et al
    Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    J Neurol. 2018;265:2980-2992.
    PubMed     Text format     Abstract available


  64. FALZONE YM, Campagnolo M, Bianco M, Dacci P, et al
    Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies.
    J Neurol. 2018;265:2927-2933.
    PubMed     Text format     Abstract available


  65. DORST J, Ludolph AC, Senel M, Tumani H, et al
    Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.
    J Neurol. 2018;265:2906-2915.
    PubMed     Text format     Abstract available


    November 2018
  66. MEGNA R, Alfano B, Lanzillo R, Costabile T, et al
    Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    J Neurol. 2018 Nov 29. pii: 10.1007/s00415-018-9139.
    PubMed     Text format     Abstract available


  67. KILJAN S, Meijer KA, Steenwijk MD, Pouwels PJW, et al
    Structural network topology relates to tissue properties in multiple sclerosis.
    J Neurol. 2018 Nov 22. pii: 10.1007/s00415-018-9130.
    PubMed     Text format     Abstract available


  68. HARDING KE, Robertson NP
    New rare genetic variants in multiple sclerosis.
    J Neurol. 2018 Nov 20. pii: 10.1007/s00415-018-9128.
    PubMed     Text format    


  69. RIEDERER I, Muhlau M, Hoshi MM, Zimmer C, et al
    Detecting optic nerve lesions in clinically isolated syndrome and multiple sclerosis: double-inversion recovery magnetic resonance imaging in comparison with visually evoked potentials.
    J Neurol. 2018 Nov 16. pii: 10.1007/s00415-018-9114.
    PubMed     Text format     Abstract available


  70. BAUMGARTNER A, Rauer S, Hottenrott T, Leypoldt F, et al
    Admission diagnoses of patients later diagnosed with autoimmune encephalitis.
    J Neurol. 2018 Nov 12. pii: 10.1007/s00415-018-9105.
    PubMed     Text format     Abstract available


  71. SAEZ MS, Rojas JI, Lorenzon MV, Sanchez F, et al
    Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires.
    J Neurol. 2018 Nov 1. pii: 10.1007/s00415-018-9106.
    PubMed     Text format     Abstract available


  72. STAMPANONI BASSI M, Iezzi E, Landi D, Monteleone F, et al
    Delayed treatment of MS is associated with high CSF levels of IL-6 and IL-8 and worse future disease course.
    J Neurol. 2018;265:2540-2547.
    PubMed     Text format     Abstract available


    October 2018
  73. ELLRICHMANN G, Bolz J, Peschke M, Duscha A, et al
    Peripheral CD19(+) B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.
    J Neurol. 2018 Oct 30. pii: 10.1007/s00415-018-9092.
    PubMed     Text format     Abstract available


  74. MCLAUGHLIN L, Clarke L, Khalilidehkordi E, Butzkueven H, et al
    Vitamin D for the treatment of multiple sclerosis: a meta-analysis.
    J Neurol. 2018 Oct 3. pii: 10.1007/s00415-018-9074.
    PubMed     Text format     Abstract available


  75. TOMMASIN S, De Giglio L, Ruggieri S, Petsas N, et al
    Relation between functional connectivity and disability in multiple sclerosis: a non-linear model.
    J Neurol. 2018 Oct 1. pii: 10.1007/s00415-018-9075.
    PubMed     Text format     Abstract available


    September 2018
  76. PROSPERINI L, Annovazzi P, Boffa L, Buscarinu MC, et al
    No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study.
    J Neurol. 2018 Sep 26. pii: 10.1007/s00415-018-9070.
    PubMed     Text format     Abstract available


  77. TUDOR KI, Eames S, Haslam C, Chataway J, et al
    Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis.
    J Neurol. 2018 Sep 19. pii: 10.1007/s00415-018-9064.
    PubMed     Text format     Abstract available


  78. LI F, Hotter B, Swierzy M, Ismail M, et al
    Generalization after ocular onset in myasthenia gravis: a case series in Germany.
    J Neurol. 2018 Sep 17. pii: 10.1007/s00415-018-9056.
    PubMed     Text format     Abstract available


  79. FAKIH R, Matiello M, Chitnis T, Stankiewicz JM, et al
    Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    J Neurol. 2018 Sep 10. pii: 10.1007/s00415-018-9050.
    PubMed     Text format     Abstract available


  80. GAETANI L, Prosperini L, Mancini A, Eusebi P, et al
    2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes.
    J Neurol. 2018 Sep 8. pii: 10.1007/s00415-018-9048.
    PubMed     Text format     Abstract available


  81. LY LT, Kreye J, Jurek B, Leubner J, et al
    Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9042.
    PubMed     Text format     Abstract available


  82. CAMBRON M, Reynders T, Debruyne J, Reyngoudt H, et al
    Targeting phosphocreatine metabolism in relapsing-remitting multiple sclerosis: evaluation with brain MRI, (1)H and (31)P MRS, and clinical and cognitive testing.
    J Neurol. 2018 Sep 5. pii: 10.1007/s00415-018-9039.
    PubMed     Text format     Abstract available


  83. VAN LIEVERLOO GGA, Peric S, Doneddu PE, Gallia F, et al
    Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone.
    J Neurol. 2018;265:2052-2059.
    PubMed     Text format     Abstract available


    August 2018
  84. FILSER M, Schreiber H, Pottgen J, Ullrich S, et al
    The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.
    J Neurol. 2018 Aug 31. pii: 10.1007/s00415-018-9034.
    PubMed     Text format     Abstract available


  85. BABER U, Bouley A, Egnor E, Sloane JA, et al
    Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients.
    J Neurol. 2018 Aug 14. pii: 10.1007/s00415-018-8996.
    PubMed     Text format     Abstract available


  86. ALEKSEEVA TM, Gavrilov YV, Kreis OA, Valko PO, et al
    Fatigue in patients with myasthenia gravis.
    J Neurol. 2018 Aug 11. pii: 10.1007/s00415-018-8995.
    PubMed     Text format     Abstract available


  87. RUMPF JJ, Dietrich S, Stoppe M, Fricke C, et al
    Compromised tDCS-induced facilitation of motor consolidation in patients with multiple sclerosis.
    J Neurol. 2018 Aug 6. pii: 10.1007/s00415-018-8993.
    PubMed     Text format     Abstract available


  88. SEITZ CB, Droby A, Zaubitzer L, Kramer J, et al
    Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging.
    J Neurol. 2018 Aug 2. pii: 10.1007/s00415-018-8988.
    PubMed     Text format     Abstract available


  89. MALLUCCI G, Annovazzi P, Miante S, Torri-Clerici V, et al
    Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study.
    J Neurol. 2018;265:1850-1859.
    PubMed     Text format     Abstract available


  90. CAO D, Guo X, Yuan T, Hao J, et al
    Diagnosing chronic inflammatory demyelinating polyradiculoneuropathy with triple stimulation technique.
    J Neurol. 2018;265:1916-1921.
    PubMed     Text format     Abstract available


    July 2018
  91. FROHLICH K, Winder K, Linker RA, Huhn K, et al
    Lesion correlates of secondary paroxysmal dyskinesia in multiple sclerosis.
    J Neurol. 2018 Jul 31. pii: 10.1007/s00415-018-8989.
    PubMed     Text format     Abstract available


  92. COCOZZA S, Pontillo G, Russo C, Russo CV, et al
    Cerebellum and cognition in progressive MS patients: functional changes beyond atrophy?
    J Neurol. 2018 Jul 28. pii: 10.1007/s00415-018-8985.
    PubMed     Text format     Abstract available


  93. BALLOY G, Pelletier J, Suchet L, Lebrun C, et al
    Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
    J Neurol. 2018 Jul 27. pii: 10.1007/s00415-018-8984.
    PubMed     Text format     Abstract available


  94. BARONE S, Caligiuri ME, Valentino P, Cherubini A, et al
    Multimodal assessment of normal-appearing corpus callosum is a useful marker of disability in relapsing-remitting multiple sclerosis: an MRI cluster analysis study.
    J Neurol. 2018 Jul 26. pii: 10.1007/s00415-018-8980.
    PubMed     Text format     Abstract available


  95. GALGANI S, Prosperini L, Haggiag S, Tortorella C, et al
    Early transient asymptomatic neutropenia associated with alemtuzumab treatment in multiple sclerosis: a case report.
    J Neurol. 2018 Jul 17. pii: 10.1007/s00415-018-8976.
    PubMed     Text format    


  96. BOST C, Chanson E, Picard G, Meyronet D, et al
    Malignant tumors in autoimmune encephalitis with anti-NMDA receptor antibodies.
    J Neurol. 2018 Jul 12. pii: 10.1007/s00415-018-8970.
    PubMed     Text format     Abstract available


  97. ALADRO Y, Lopez-Alvarez L, Sanchez-Reyes JM, Hernandez-Tamames JA, et al
    Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis.
    J Neurol. 2018 Jul 11. pii: 10.1007/s00415-018-8965.
    PubMed     Text format     Abstract available


  98. KALLWEIT U, Bassetti CLA, Oberholzer M, Fronczek R, et al
    Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis : Six new cases and a literature review.
    J Neurol. 2018 Jul 4. pii: 10.1007/s00415-018-8949.
    PubMed     Text format     Abstract available


    June 2018
  99. BAJRAMI A, Pitteri M, Castellaro M, Pizzini F, et al
    The effect of fingolimod on focal and diffuse grey matter damage in active MS patients.
    J Neurol. 2018 Jun 25. pii: 10.1007/s00415-018-8952.
    PubMed     Text format     Abstract available


  100. MOTTE J, Kneiphof J, Strassburger-Krogias K, Klasing A, et al
    Detection of JC virus archetype in cerebrospinal fluid in a MS patient with dimethylfumarate treatment without lymphopenia or signs of PML.
    J Neurol. 2018 Jun 15. pii: 10.1007/s00415-018-8931.
    PubMed     Text format     Abstract available


    May 2018
  101. MARSHALL I, Thrippleton MJ, Bastin ME, Mollison D, et al
    Characterisation of tissue-type metabolic content in secondary progressive multiple sclerosis: a magnetic resonance spectroscopic imaging study.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8903.
    PubMed     Text format     Abstract available


  102. WAGNER JN, Schwarz G, Puttinger G, Hengsberger AM, et al
    Anti-NMDA receptor encephalitis triggered by epilepsy surgery.
    J Neurol. 2018 May 30. pii: 10.1007/s00415-018-8918.
    PubMed     Text format    


  103. YAMAGUCHI H, Sakai K, Goto Y, Yamada M, et al
    Autoimmune hepatitis induced by a single injection of interferon-beta 1a in a patient with multiple sclerosis.
    J Neurol. 2018 May 29. pii: 10.1007/s00415-018-8912.
    PubMed     Text format    


  104. SANTANGELO G, Bisecco A, Trojano L, Sacco R, et al
    Cognitive performance in multiple sclerosis: the contribution of intellectual enrichment and brain MRI measures.
    J Neurol. 2018 May 26. pii: 10.1007/s00415-018-8905.
    PubMed     Text format     Abstract available


  105. ALCALA C, Gascon F, Perez-Miralles F, Gil-Perotin S, et al
    Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.
    J Neurol. 2018 May 21. pii: 10.1007/s00415-018-8899.
    PubMed     Text format     Abstract available


  106. KOCSIK AS, Klein DE, Liedke M, Kaunzner UW, et al
    Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.
    J Neurol. 2018;265:1226-1229.
    PubMed     Text format     Abstract available


  107. OPFER R, Ostwaldt AC, Walker-Egger C, Manogaran P, et al
    Within-patient fluctuation of brain volume estimates from short-term repeated MRI measurements using SIENA/FSL.
    J Neurol. 2018;265:1158-1165.
    PubMed     Text format     Abstract available


  108. TALLANTYRE EC, Whittam DH, Jolles S, Paling D, et al
    Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation.
    J Neurol. 2018;265:1115-1122.
    PubMed     Text format     Abstract available


    April 2018
  109. RASUL T, Frederiksen JL
    Link between overweight/obese in children and youngsters and occurrence of multiple sclerosis.
    J Neurol. 2018 Apr 26. pii: 10.1007/s00415-018-8869.
    PubMed     Text format     Abstract available


  110. HUHN K, Bayas A, Doerck S, Frank B, et al
    Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
    J Neurol. 2018 Apr 25. pii: 10.1007/s00415-018-8871.
    PubMed     Text format     Abstract available


  111. TAVAZZI E, Bergsland N, Cattaneo D, Gervasoni E, et al
    Effects of motor rehabilitation on mobility and brain plasticity in multiple sclerosis: a structural and functional MRI study.
    J Neurol. 2018 Apr 7. pii: 10.1007/s00415-018-8859.
    PubMed     Text format     Abstract available


  112. CABRE P, Mejdoubi M, Jeannin S, Merle H, et al
    Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study.
    J Neurol. 2018;265:917-925.
    PubMed     Text format     Abstract available


    March 2018
  113. COGHE G, Corona F, Marongiu E, Fenu G, et al
    Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial.
    J Neurol. 2018 Mar 24. pii: 10.1007/s00415-018-8836.
    PubMed     Text format     Abstract available


  114. NAKKEN O, Lindstrom JC, Holmoy T
    Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.
    J Neurol. 2018 Mar 21. pii: 10.1007/s00415-018-8832.
    PubMed     Text format     Abstract available


  115. CERONIE B, Jacobs BM, Baker D, Dubuisson N, et al
    Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
    J Neurol. 2018 Mar 17. pii: 10.1007/s00415-018-8830.
    PubMed     Text format     Abstract available


  116. LANZILLO R, Prosperini L, Gasperini C, Moccia M, et al
    A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    J Neurol. 2018 Mar 16. pii: 10.1007/s00415-018-8831.
    PubMed     Text format     Abstract available


  117. AOYAMA S, Mori M, Uzawa A, Uchida T, et al
    Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.
    J Neurol. 2018 Mar 12. pii: 10.1007/s00415-018-8813.
    PubMed     Text format     Abstract available


  118. DEVONSHIRE V, Phillips R, Wass H, Da Roza G, et al
    Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    J Neurol. 2018 Mar 10. pii: 10.1007/s00415-018-8822.
    PubMed     Text format     Abstract available


  119. HOTTENROTT T, Schorb E, Fritsch K, Dersch R, et al
    The MRZ reaction and a quantitative intrathecal IgG synthesis may be helpful to differentiate between primary central nervous system lymphoma and multiple sclerosis.
    J Neurol. 2018 Mar 6. pii: 10.1007/s00415-018-8779.
    PubMed     Text format     Abstract available


  120. LOREFICE L, Fenu G, Pitzalis R, Scalas G, et al
    Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A case-control MRI study.
    J Neurol. 2018 Mar 5. pii: 10.1007/s00415-018-8811.
    PubMed     Text format     Abstract available


  121. KANEKO A, Kaneko J, Tominaga N, Kanazawa N, et al
    Pitfalls in clinical diagnosis of anti-NMDA receptor encephalitis.
    J Neurol. 2018;265:586-596.
    PubMed     Text format     Abstract available


    February 2018
  122. BROICHER SD, Filli L, Geisseler O, Germann N, et al
    Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8796.
    PubMed     Text format     Abstract available


  123. VAN DER VUURST DE VRIES RM, Mescheriakova JY, Runia TF, Siepman TAM, et al
    Smoking at time of CIS increases the risk of clinically definite multiple sclerosis.
    J Neurol. 2018 Feb 20. pii: 10.1007/s00415-018-8780.
    PubMed     Text format     Abstract available


  124. BELL JS, Spencer JI, Yates RL, DeLuca GC, et al
    The cortical blood-brain barrier in multiple sclerosis: a gateway to progression?
    J Neurol. 2018 Feb 13. pii: 10.1007/s00415-017-8727.
    PubMed     Text format    


  125. ESPOSITO F, Ferre L, Clarelli F, Rocca MA, et al
    Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    J Neurol. 2018 Feb 12. pii: 10.1007/s00415-018-8791.
    PubMed     Text format     Abstract available


  126. ARNETH B
    Up-to-date knowledge about the association between multiple sclerosis and the reactivation of human endogenous retrovirus infections.
    J Neurol. 2018 Feb 8. pii: 10.1007/s00415-018-8783.
    PubMed     Text format     Abstract available


  127. SOLARO C, Cella M, Signori A, Martinelli V, et al
    Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria.
    J Neurol. 2018 Feb 5. pii: 10.1007/s00415-018-8758.
    PubMed     Text format     Abstract available


  128. KALRON A, Allali G, Achiron A
    Cerebellum and cognition in multiple sclerosis: the fall status matters.
    J Neurol. 2018 Feb 2. pii: 10.1007/s00415-018-8774.
    PubMed     Text format     Abstract available


  129. WINDER K, Linker RA, Seifert F, Deutsch M, et al
    Insular multiple sclerosis lesions are associated with erectile dysfunction.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8763.
    PubMed     Text format     Abstract available


  130. LANDFELDT E, Castelo-Branco A, Svedbom A, Lofroth E, et al
    The long-term impact of early treatment of multiple sclerosis on the risk of disability pension.
    J Neurol. 2018 Feb 1. pii: 10.1007/s00415-018-8764.
    PubMed     Text format     Abstract available


  131. FRAU J, Carai M, Coghe G, Fenu G, et al
    Long-term follow-up more than 10 years after HSCT: a monocentric experience.
    J Neurol. 2018;265:410-416.
    PubMed     Text format     Abstract available


  132. AKDAL G, Tanriverdizade T, Sengun I, Bademkiran F, et al
    Vestibular impairment in chronic inflammatory demyelinating polyneuropathy.
    J Neurol. 2018;265:381-387.
    PubMed     Text format     Abstract available


  133. WANG R, Lai XH, Liu X, Li YJ, et al
    Brain magnetic resonance-imaging findings of anti-N-methyl-D-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients.
    J Neurol. 2018;265:362-369.
    PubMed     Text format     Abstract available


  134. HONGELL K, Silva DG, Ritter S, Meier DP, et al
    Efficacy and safety outcomes in vitamin D supplement users in the fingolimod phase 3 trials.
    J Neurol. 2018;265:348-355.
    PubMed     Text format     Abstract available


    January 2018
  135. VOGRIG A, Joubert B, Ducray F, Thomas L, et al
    Glioblastoma as differential diagnosis of autoimmune encephalitis.
    J Neurol. 2018 Jan 30. pii: 10.1007/s00415-018-8767.
    PubMed     Text format     Abstract available


  136. GILHUS NE, Romi F, Hong Y, Skeie GO, et al
    Myasthenia gravis and infectious disease.
    J Neurol. 2018 Jan 25. pii: 10.1007/s00415-018-8751.
    PubMed     Text format     Abstract available


  137. FIENE M, Rufener KS, Kuehne M, Matzke M, et al
    Electrophysiological and behavioral effects of frontal transcranial direct current stimulation on cognitive fatigue in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8754.
    PubMed     Text format     Abstract available


  138. LEAVITT VM, Tosto G, Riley CS
    Cognitive phenotypes in multiple sclerosis.
    J Neurol. 2018 Jan 22. pii: 10.1007/s00415-018-8747.
    PubMed     Text format     Abstract available


  139. DI GREGORIO M, Gaetani L, Eusebi P, Floridi P, et al
    Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
    J Neurol. 2018 Jan 11. pii: 10.1007/s00415-017-8726.
    PubMed     Text format     Abstract available


  140. MCMACKEN G, Whittaker RG, Evangelista T, Abicht A, et al
    Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients.
    J Neurol. 2018;265:194-203.
    PubMed     Text format     Abstract available


  141. ALENDA R, Costa-Frossard L, Alvarez-Lafuente R, Espejo C, et al
    Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
    J Neurol. 2018;265:24-31.
    PubMed     Text format     Abstract available


    December 2017
  142. FRAU J, Villar LM, Sardu C, Secci MA, et al
    Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8716.
    PubMed     Text format     Abstract available


  143. BRENTON JN, Schreiner T, Karoscik K, Richter M, et al
    Attitudes, perceptions, and use of marijuana in youth with multiple sclerosis.
    J Neurol. 2017 Dec 22. pii: 10.1007/s00415-017-8715.
    PubMed     Text format     Abstract available


  144. SHRIBMAN S, Hasan H, Hadavi S, Giovannoni G, et al
    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis.
    J Neurol. 2017 Dec 4. pii: 10.1007/s00415-017-8690.
    PubMed     Text format     Abstract available


    November 2017
  145. THALER C, Faizy TD, Sedlacik J, Bester M, et al
    The use of multiparametric quantitative magnetic resonance imaging for evaluating visually assigned lesion groups in patients with multiple sclerosis.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8683.
    PubMed     Text format     Abstract available


  146. CONRADSSON D, Ytterberg C, von Koch L, Johansson S, et al
    Changes in disability in people with multiple sclerosis: a 10-year prospective study.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8676.
    PubMed     Text format     Abstract available


  147. ELIASDOTTIR O, Hildeman A, Longfils M, Nerman O, et al
    A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland.
    J Neurol. 2017 Nov 20. doi: 10.1007/s00415-017-8665.
    PubMed     Text format     Abstract available


  148. RUPRECHT K, Wildemann B, Jarius S
    Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature.
    J Neurol. 2017 Nov 2. doi: 10.1007/s00415-017-8656.
    PubMed     Text format     Abstract available


    October 2017
  149. COMI G, Patti F, Rocca MA, Mattioli FC, et al
    Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8642.
    PubMed     Text format     Abstract available


  150. PARDO G, Jones DE
    Correction to: The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Oct 23. doi: 10.1007/s00415-017-8633.
    PubMed     Text format     Abstract available


  151. ABBOUD H, Rossman I, Mealy MA, Hill E, et al
    Neuronal autoantibodies: differentiating clinically relevant and clinically irrelevant results.
    J Neurol. 2017 Oct 3. doi: 10.1007/s00415-017-8627.
    PubMed     Text format     Abstract available


    September 2017
  152. WANG L, Zhang S, Xi J, Li W, et al
    Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
    J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616.
    PubMed     Text format     Abstract available


  153. LOREFICE L, Coghe G, Fenu G, Porta M, et al
    'Timed up and go' and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis.
    J Neurol. 2017 Sep 11. doi: 10.1007/s00415-017-8612.
    PubMed     Text format     Abstract available


  154. PARDO G, Jones DE
    The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.
    J Neurol. 2017 Sep 6. doi: 10.1007/s00415-017-8594.
    PubMed     Text format     Abstract available


    August 2017
  155. LATTANZI S, Danni M, Taffi R, Cerqua R, et al
    Persistence to oral disease-modifying therapies in multiple sclerosis patients.
    J Neurol. 2017 Aug 22. doi: 10.1007/s00415-017-8595.
    PubMed     Text format     Abstract available


  156. HRASTELJ J, Robertson N
    Genetics of disease severity in multiple sclerosis, Alzheimer's disease, and Huntington's disease: rejuvenating genome-wide association studies.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8584.
    PubMed     Text format    


  157. FINKE C, Bartels F, Lutt A, Pruss H, et al
    High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients.
    J Neurol. 2017 Aug 7. doi: 10.1007/s00415-017-8582.
    PubMed     Text format     Abstract available


    July 2017
  158. EICHINGER P, Wiestler H, Zhang H, Biberacher V, et al
    A novel imaging technique for better detecting new lesions in multiple sclerosis.
    J Neurol. 2017 Jul 29. doi: 10.1007/s00415-017-8576.
    PubMed     Text format     Abstract available


  159. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Erratum to: Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jul 10. doi: 10.1007/s00415-017-8556.
    PubMed     Text format    


    June 2017
  160. CASEY JP, Hirouchi T, Hisatsune C, Lynch B, et al
    A novel gain-of-function mutation in the ITPR1 suppressor domain causes spinocerebellar ataxia with altered Ca2+ signal patterns.
    J Neurol. 2017 Jun 15. doi: 10.1007/s00415-017-8545.
    PubMed     Text format     Abstract available


  161. SCHOSER B, Eymard B, Datt J, Mantegazza R, et al
    Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
    J Neurol. 2017 Jun 12. doi: 10.1007/s00415-017-8541.
    PubMed     Text format     Abstract available


  162. HAGSTROM IT, Schneider R, Bellenberg B, Salmen A, et al
    Relevance of early cervical cord volume loss in the disease evolution of clinically isolated syndrome and early multiple sclerosis: a 2-year follow-up study.
    J Neurol. 2017 Jun 9. doi: 10.1007/s00415-017-8537.
    PubMed     Text format     Abstract available


    May 2017
  163. BRITZE J, Pihl-Jensen G, Frederiksen JL
    Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis.
    J Neurol. 2017 May 31. doi: 10.1007/s00415-017-8531.
    PubMed     Text format     Abstract available


  164. DIBLEY L, Coggrave M, McClurg D, Woodward S, et al
    "It's just horrible": a qualitative study of patients' and carers' experiences of bowel dysfunction in multiple sclerosis.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8527.
    PubMed     Text format     Abstract available


  165. RATH J, Mauritz M, Zulehner G, Hilger E, et al
    Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study.
    J Neurol. 2017 May 26. doi: 10.1007/s00415-017-8518.
    PubMed     Text format     Abstract available


  166. RIVIERE E, Cohen Aubart F, Maisonobe T, Maurier F, et al
    Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study.
    J Neurol. 2017 May 23. doi: 10.1007/s00415-017-8519.
    PubMed     Text format     Abstract available


  167. FOULON S, Maura G, Dalichampt M, Alla F, et al
    Prevalence and mortality of patients with multiple sclerosis in France in 2012: a study based on French health insurance data.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8513.
    PubMed     Text format     Abstract available


  168. CORDTS I, Bodart N, Hartmann K, Karagiorgou K, et al
    Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis.
    J Neurol. 2017 May 17. doi: 10.1007/s00415-017-8514.
    PubMed     Text format     Abstract available


  169. LATTANZI S, Cagnetti C, Danni M, Provinciali L, et al
    Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis.
    J Neurol. 2017 May 10. doi: 10.1007/s00415-017-8505.
    PubMed     Text format     Abstract available


    April 2017
  170. HARDING K, Tilling K, MacIver C, Willis M, et al
    Seasonal variation in multiple sclerosis relapse.
    J Neurol. 2017 Apr 19. doi: 10.1007/s00415-017-8485.
    PubMed     Text format     Abstract available


  171. SARTORI A, Abdoli M, Freedman MS
    Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study.
    J Neurol. 2017 Apr 17. doi: 10.1007/s00415-017-8487.
    PubMed     Text format     Abstract available


  172. HAINLINE C, Rizzo JR, Hudson TE, Dai W, et al
    Capturing saccades in multiple sclerosis with a digitized test of rapid number naming.
    J Neurol. 2017 Apr 7. doi: 10.1007/s00415-017-8484.
    PubMed     Text format     Abstract available


  173. CHOI HA, Lee MJ, Chung CS
    Characteristics of hypertrophic pachymeningitis in patients with granulomatosis with polyangiitis.
    J Neurol. 2017;264:724-732.
    PubMed     Text format     Abstract available


  174. BARTOLINI L, Muscal E
    Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey.
    J Neurol. 2017;264:647-653.
    PubMed     Text format     Abstract available


    March 2017
  175. HONG Y, Skeie GO, Zisimopoulou P, Karagiorgou K, et al
    Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms.
    J Neurol. 2017 Mar 31. doi: 10.1007/s00415-017-8478.
    PubMed     Text format     Abstract available


  176. PREZIOSA P, Martinelli V, Ferre L, Guaschino C, et al
    Moyamoya disease mimicking the first attack of multiple sclerosis.
    J Neurol. 2017 Mar 17. doi: 10.1007/s00415-017-8458.
    PubMed     Text format    


  177. MCLAUCHLAN D, Robertson NP
    B cell treatments for multiple sclerosis.
    J Neurol. 2017 Mar 4. doi: 10.1007/s00415-017-8442.
    PubMed     Text format    


  178. KHAN F, Amatya B, Galea MP, Gonzenbach R, et al
    Neurorehabilitation: applied neuroplasticity.
    J Neurol. 2017;264:603-615.
    PubMed     Text format     Abstract available


    February 2017
  179. NIJ BIJVANK JA, Balk LJ, Tan HS, Uitdehaag BM, et al
    A rare cause for visual symptoms in multiple sclerosis: posterior internuclear ophthalmoplegia of Lutz, a historical misnomer.
    J Neurol. 2017 Feb 13. doi: 10.1007/s00415-017-8412.
    PubMed     Text format    


  180. MALONEY E, Molloy A, Al Hussona M, O'Donnell L, et al
    Natalizumab-associated progressive multifocal leukoencephalopathy: successful treatment without plasma exchange and its associated risks.
    J Neurol. 2017;264:401-403.
    PubMed     Text format    


    January 2017
  181. BIANCHI A, Bartolini E, Melani F, Guerrini R, et al
    Isolated recurrent myelitis in a 7-year-old child with serum aquaporin-4 IgG antibodies.
    J Neurol. 2017;264:179-181.
    PubMed     Text format    


    December 2016
  182. GIORLI E, Franciotta D, Beronio A, Amodeo C, et al
    Late AQP4-IgG seroconversion and shrinking of brainstem MRI lesions in a patient with overlapping CIS/NMOSD.
    J Neurol. 2016;263:2549-2551.
    PubMed     Text format    


  183. HUSS AM, Halbgebauer S, Ockl P, Trebst C, et al
    Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome.
    J Neurol. 2016;263:2499-2504.
    PubMed     Text format     Abstract available


  184. HUANG Q, Wu Y, Qin R, Wei X, et al
    Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis.
    J Neurol. 2016;263:2446-2455.
    PubMed     Text format     Abstract available


    November 2016
  185. BLOCK VJ, Lizee A, Crabtree-Hartman E, Bevan CJ, et al
    Continuous daily assessment of multiple sclerosis disability using remote step count monitoring.
    J Neurol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  186. PIETRZAK K, Grzybowski A, Kaczmarczyk J
    Georges Guillain (1876-1961).
    J Neurol. 2016;263:2148-9.
    PubMed     Text format    


  187. ABSINTA M, Reich DS, Filippi M
    Spring cleaning: time to rethink imaging research lines in MS?
    J Neurol. 2016;263:1893-902.
    PubMed     Text format     Abstract available


    September 2016
  188. MAILLART E, Papeix C, Mellerio C, Bertrand A, et al
    Extensive and severe CNS demyelination associated with golimumab therapy.
    J Neurol. 2016;263:1869-71.
    PubMed     Text format    


  189. LOZERON P, Ribrag V, Adams D, Brisset M, et al
    Is distal motor and/or sensory demyelination a distinctive feature of anti-MAG neuropathy?
    J Neurol. 2016;263:1761-70.
    PubMed     Text format     Abstract available


  190. ANNOVAZZI P, Capobianco M, Moiola L, Patti F, et al
    Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study.
    J Neurol. 2016;263:1727-35.
    PubMed     Text format     Abstract available


    August 2016
  191. ZURAWSKI J, Flinn A, Sklover L, Sloane JA, et al
    Relapse frequency in transitioning from natalizumab to dimethyl fumarate: assessment of risk factors.
    J Neurol. 2016;263:1511-7.
    PubMed     Text format     Abstract available


    July 2016
  192. ZHOU H, Zhao S, Yin D, Chen X, et al
    Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
    J Neurol. 2016;263:1382-9.
    PubMed     Text format     Abstract available


  193. JEONG IH, Kim HJ, Kim NH, Jeong KS, et al
    Subclinical primary retinal pathology in neuromyelitis optica spectrum disorder.
    J Neurol. 2016;263:1343-8.
    PubMed     Text format     Abstract available


  194. BALK LJ, Cruz-Herranz A, Albrecht P, Arnow S, et al
    Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study.
    J Neurol. 2016;263:1323-31.
    PubMed     Text format     Abstract available


  195. HAVRDOVA E, Belova A, Goloborodko A, Tisserant A, et al
    Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study.
    J Neurol. 2016;263:1287-95.
    PubMed     Text format     Abstract available


    June 2016
  196. BRIER MR, Day GS, Snyder AZ, Tanenbaum AB, et al
    N-methyl-D-aspartate receptor encephalitis mediates loss of intrinsic activity measured by functional MRI.
    J Neurol. 2016;263:1083-91.
    PubMed     Text format     Abstract available


  197. GRIMM A, Vittore D, Schubert V, Rasenack M, et al
    Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
    J Neurol. 2016;263:1074-82.
    PubMed     Text format     Abstract available


    May 2016
  198. VINJAM MR, Shanmugarajah P, Ford HL
    Ophthalmoplegia heralding the onset of anti-amphiphysin related paraneoplastic stiff person syndrome.
    J Neurol. 2016;263:1017-8.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: